FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...
The PRIMA system is a subretinal implant designed to restore central vision in GA patients by replacing failed photoreceptors ...
The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback